Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate NDC 42385-929

NDC codes

FDA NDC Directory

Product NDC (as listed)42385-929Labeler and product segments. Claims need a package NDC.

Product NDC at billing width42385-0929Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
42385-929-18	42385092918	180 TABLET, FILM COATED in 1 BOTTLE (42385-929-18)Marketed from May 14, 2020
42385-929-30	42385092930	30 TABLET, FILM COATED in 1 BOTTLE (42385-929-30)Marketed from May 14, 2020
42385-929-31	42385092931	30 TABLET, FILM COATED in 1 BOTTLE (42385-929-31)Marketed from May 14, 2020
42385-929-82	42385092982	180 TABLET, FILM COATED in 1 BOTTLE (42385-929-82)Marketed from May 14, 2020
42385-929-90	42385092990	90 TABLET, FILM COATED in 1 BOTTLE (42385-929-90)Marketed from May 14, 2020
42385-929-91	42385092991	90 TABLET, FILM COATED in 1 BOTTLE (42385-929-91)Marketed from May 14, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
Generic name (nonproprietary): efavirenz, lamivudine and tenofovir disoproxil fumarate
Active ingredients: Efavirenz — 400 mg/1Lamivudine — 300 mg/1Tenofovir disoproxil fumarate — 300 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Laurus Labs Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213038
Marketing start: May 14, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Cytochrome P450 2B6 Inducers (Mechanism)Cytochrome P450 2C19 Inhibitors (Mechanism)Cytochrome P450 2C9 Inhibitors (Mechanism)Cytochrome P450 3A Inducers (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)Non-Nucleoside Analog (EXT)Non-Nucleoside Reverse Transcriptase Inhibitors (Mechanism)Nucleoside Reverse Transcriptase Inhibitors (Mechanism)Nucleoside Reverse Transcriptase Inhibitors (Mechanism)Nucleosides (Chemical structure)
Identifiers: Product ID 42385-929_80228c3a-152e-4170-9469-b4e13b137bcbSPL ID 80228c3a-152e-4170-9469-b4e13b137bcbSPL set ID 98342153-b9de-4318-aac4-9f8d19590cd7RxCUI 2001424UNII JE6H2O27P8, 2T8Q726O95, OTT9J7900IUPC 0342385929317
Pharmacologic class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N442385092918 followed by a unit qualifier and the quantity

Package 42385-0929-18. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Label details couldn’t be retrieved right now. Open the label on DailyMed.